Clindamycin HCl

InformationClindamycin HCl Clindamycin HCl inhibits protein synthesis by acting on the 50S ribosomal , used for the treatment of bacterial infections.In vitroClindamycin is a classical inhibitor of bacterial protein synthesis, by binding to the 23S ribosomal RNA of the 50S ribosomal subunit.In vivoClindamycin hydrochloride results in fast absorption after oral administration in dogs, with a mean absorption time (MAT) of 0.87 hour, and bioavailability is 72.55%. Clindamycin hydrochloride results in total clearance (CL) of Clindamycin after both IV and oral administration (0.503 vs. 0.458 L/h/kg) in dogs. Clindamycin hydrochloride results in volume of distribution at steady-state (IV) at 2.48 L/kg, indicating a wide distribution of clindamycin in body fluids and tissues. Clindamycin serum concentrations after IV and oral administration remain above 0.5 μg/mL approximately for 10 hours. Clindamycin hydrochloride significantly reduces oral malodor from the dogs/' baseline levels through 42 days. Clindamycin hydrochloride also results in significant reductions in dental plaque, dental calculus, and gingival bleeding in dogs. Clindamycin hydrochloride (2.5 mg/lb), after ultrasonic scaling, root planing, and polishing (USRP) , has a significant effect on plaque and pocket depth measures of periodontal disease but not on gingivitis in canine. Clindamycin hydrochloride results in complete remission ratio of 71.4% (15/21) in dogs with canine superficial bacterial pyoderma after treat within 14 to 28 days.Cell Datacell lines：Concentrations：Incubation Time：Powder Purity:. Specification: 10mM in DMSO Molecular Formula: C18H33ClN2O5S·HCl Molecular Weight: 461.44